

# SANDU PHARMACEUTICALS LTD.

**Regd. Office:** Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa-403511.  
Tel: +91 832 2407474 / 6715000, Fax: +91 832 2407008, E-mail: sandupharma@sandu.in

L24233GA1985PLC001587

**Ref:** SPL/CORP SEC/BSE/2017-18/545

To,  
Bombay Stock Exchange Limited,  
Corporate Services Division,  
Floor 25, P J Tower, Dalal Street,  
Mumbai 400001

Dated: 20/10/2017

**Kind Attn:** Department of Corporate Services Division.

**SUB:** Your email dated 06<sup>th</sup> October 2017 reporting Discrepancies in the Financial Result of the Company for the Quarter ended June 2017.

Madam/ Sir,


In this regard please find enclosed herewith Financial Results of the Company for the Quarter ended 30<sup>th</sup> June 2017 as per Schedule III format of Companies Act 2013.

You are requested to take the same on record and oblige.

Thanking you,

Yours Faithfully,

**For Sandu Pharmaceuticals Limited**

  
Company Secretary





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

REGD.OFFICE- PLOT NOS. 25,26,29 & 30, PILERNE INDUSTRIAL ESTATE,

MARRA, SALIGAO, BARDEZ GOA- 403 511.

STATEMENT OF UNAUDITED RESULTS FOR THE PERIOD ENDED 30/06/17

PART I

(Rs. In Lakhs except EPS data)

Particulars	3 months ended	Preceeding 3	3 months ended	Previous year
	30/06/17 Ind AS	months ended 31/03/17 I-GAAP #	30/06/16 Ind AS	ended 31/03/17 I-GAAP #
(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1 Income from continuing operations				
(a) Net sales/income from operations (Net of excise duty)	677.49	1,112.16	1,013.41	4,481.81
	677.49	1,112.16	1,013.41	4,481.81
(b) Other operating income			-	-
<b>Total income from operations (net)</b>	<b>677.49</b>	<b>1,112.16</b>	<b>1,013.41</b>	<b>4,481.81</b>
2 Expenses				
(a) Cost of materials consumed	168.59	191.36	130.28	723.21
(b) Purchases of traded goods	319.16	529.72	429.51	1,736.36
(c) Changes in inventories of finished goods, work-in-progress, traded goods & Stock in Transit	(166.28)	(183.00)	15.43	15.13
(d) Employee benefits expense	133.31	159.50	112.75	536.98
(e) Depreciation and amortisation expense	11.49	18.15	17.33	72.17
(f) Other expenses	239.10	346.67	254.27	1,204.87
<b>Total expenses</b>	<b>705.37</b>	<b>1,062.40</b>	<b>959.56</b>	<b>4,288.72</b>
3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(27.88)	49.75	53.85	193.09
4 Other income	4.93	2.01	0.27	39.17
5 <b>Profit / (Loss) from ordinary activities</b> before finance costs and exceptional items (3 + 4)	<b>(22.95)</b>	<b>51.76</b>	<b>54.12</b>	<b>232.26</b>
6 Finance costs	30.70	32.00	40.35	149.41
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	(53.64)	19.76	13.76	82.86
8 Exceptional items		(9.28)	-	(9.28)
9 Profit / (Loss) from ordinary activities before tax (7 + 8)	(53.64)	19.76	13.76	92.14
10 Tax expense	-	8.69	7.65	49.76
11 <b>Net Profit / (Loss) from ordinary activities</b> after tax (9 + 10)	<b>(53.64)</b>	<b>11.07</b>	<b>6.11</b>	<b>42.38</b>
12 Extraordinary items (net of tax expense)	-	-	0.00	0.00
13 <b>Net Profit / (Loss) for the period (11 + 12)</b>	<b>(53.64)</b>	<b>11.07</b>	<b>6.11</b>	<b>42.38</b>
14 Share of profit / (loss) of associates*				
15 Minority interest *				
16 <b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *</b>	<b>(53.64)</b>	<b>11.07</b>	<b>6.11</b>	<b>42.38</b>
17 Other Comprehensive Income	0.62		4.38	
18 <b>Total Comprehensive Income for the period (16) + (17)</b> (Comprising profit / (loss) and other comprehensive income for the period)	<b>-53.02</b>		<b>10.49</b>	
19.1 Earnings per share (before extraordinary items) (of 10/- each) (not annualised):	-1.02	0.16	0.15	0.60
(a) Basic				
(b) Diluted				
19.2 Earnings per share (after extraordinary items) (of 10/- each) (not annualised):	-1.02	0.16	0.15	0.60
(a) Basic				
(b) Diluted				



